confirming EETs as primary players. Inhibition of cyclooxygenases (COXs) significantly 40 enhanced HPV in WT vessels, but attenuated HPV in sEH-KO vessels. Blocking/inhibiting 41 COX-1, prostaglandin H 2 (PGH 2 )/thromboxane A2 (TXA 2 ) receptors and TXA synthase 42 prevented the enhanced HPV in sEH-KO vessels, but had no effects on WT vessels. In 43 conclusion, an EET-dependent alteration in PG-metabolism that favors the action of 44 vasoconstrictor PGH 2 and TXA 2 potentiates HPV and hypoxia-induced elevation of RVSP in 45 sEH-deficient mice. 46 47 3 48 Key words: Epoxyeicosatrienoic acids; soluble epoxide hydrolase; hypoxic pulmonary 49 vasoconstriction; right ventricular systolic pressure; prostaglandins. 50 51 52 53
Abstract (250) 25
To test the hypothesis that epoxyeicosatrienoic acids (EETs) facilitate pulmonary responses to 26 hypoxia, male wild type (WT) and soluble epoxide hydrolase knockout (sEH-KO) mice, and WT 27 mice chronically fed a sEH inhibitor (t-TUCB; 1mg/kg/day) were used. Right ventricular systolic 28 pressure (RVSP) was recorded under control and hypoxic conditions. The control RVSP was 29 comparable among all groups. However, hypoxia elicited increases in RVSP in all groups with 30 predominance in sEH-KO and t-TUCB-treated mice. 14,15-EEZE (EET antagonist) attenuated 31 the hypoxia-induced greater elevation of RVSP in sEH-deficient mice, suggesting an EET-32 mediated increment. Exogenous 5,6-; 8,9-or 14,15-EET (0.05ng/gram body weight) did not 33 change RVSP in any conditions, but 11,12-EET enhanced RVSP under hypoxia. Isometric 34 tension was recorded from pulmonary arteries isolated from WT and sEH-KO mice, vessels that 35 behaved identically in their responsiveness to vasoactive agents and vessel stretch. Hypoxic 36 pulmonary vasoconstriction (HPV, expressed as increases in hypoxic force) was significantly 37 greater in vessels of sEH-KO than WT vessels; the enhanced component was inhibited by EEZE. 38
Treatment of WT vessels with 11,12-EET enhanced HPV to the same level as sEH-KO vessels, 39
Introduction 54 55
In the pulmonary circulation, a reduction in oxygen tension causes contraction of 56 pulmonary vascular smooth muscle, a phenomenon that is defined as hypoxic pulmonary 57 vasoconstriction (HPV). HPV in vivo, is manifested as an increase in right ventricular 58 systolic pressure (RVSP), which indicates the enhanced pulmonary artery pressure and 59 therefore, may play a role in the pathogenesis of pulmonary hypertension. A physiological 60 relevance of HPV is to acutely optimize gas exchange by shunting blood flow from hypoxic 61 alveoli towards better ventilated areas. Indeed, in response to lipopolysaccharide 62 challenge, preservation of HPV, as a function of soluble epoxide hydrolase (sEH) deficiency 63 is accompanied with an increase in the level of systemic arterial oxygenation (44). 64
However, a prolonged exposure of hypoxia followed by sustained HPV initiates 65 pathological consequences of vascular remodeling and progressive development of 66 pulmonary hypertension. Several decades have passed since the first description of HPV, 67 but its mechanism remains elusive. Within the literature, the mechanistic nature of HPV 68 varies with different species and sexes, in vivo or in vitro preparations, the duration for 69 exposure of hypoxia (acute or chronic), and vessel localization/size and cell type 70 (endothelium-dependent or independent) etc., all of which may specifically determine 71 different cellular mediators and channels involved, as well as the characteristics of 72 modulating the response (13; 27; 32; 38; 41). 73
Even though specific mechanism(s) responsible for HPV are currently unknown, an 74 alteration in the metabolism of arachidonic acid (AA) seems to be a promising target since 75 each of all three major pathways responsible for AA metabolism by lipoxygenases (33; 34), 76 cyclooxygenases (COXs) (1; 3; 22) and cytochrome P450s (CYPs) (21; 23; 24), has been 77 reported to be involved in potentiating HPV via either sensing changes in O 2 or 78 participating in mediation of the signaling (41). Among the three pathways, the CYP 79 pathway has attracted considerable attention based on its capability to serve as O 2 sensor 80 and causes a hypoxia-induced reduction in CYP ω-hydrolase production of 20-81 hydroxyeicosatetraenoic acid (20-HETE), leading to the promotion of HPV (40; 46). 82
Moreover, crucial roles of CYPs, enzymes responsible for the synthesis of 83 epoxyeicosatrienoic acids (EETs), in HPV have emerged. As reported, HPV in mice was 84 significantly attenuated by the inhibition of CYP2C9 and potentiated by overexpression of 85 CYP2C9 or downregulation/blockage of sEH, a down-stream enzyme that is responsible for 86 EET metabolism/degradation in the CYP pathway (22; 35). Indeed, in the pulmonary 87 vasculature, CYP metabolism of AA provides the majority of vasoactive compounds 88 including 20-HETE and EETs (19). As we reported previously (21), administration of 89 exogenous EETs to mice increased right ventricular systolic pressure (RVSP) in a dose-90 dependent manner, suggesting that EETs elicit direct pulmonary vasoconstriction (29; 47). 91
Moreover, EET-induced increases in RVSP became more predominant under hypoxia, 92 revealing a positive feedback between EETs and hypoxia during the process of HPV (21). 93
Alternatively, we have also found that increased bioavailability of pulmonary EETs 94 by sEH gene deletion did not affect basal pulmonary artery pressure, but dramatically 95 enhanced U46619 (a thromboxane analog)-induced elevation of RVSP (22), indicating that 96 an EET-potentiation of constrictor prostaglandins appeares to be involved in pulmonary 97 vasoconstriction. Thus, a question was raised as whether CYP-derived EETs solely facilitate 98 HPV, or take a part in an AA cascade pathway that links the O 2 sensor/hypoxia to 99 vasoconstriction. With respect to interactions among EET, hypoxia and cyclooxygenases, 100 6 we designed experiments aimed to test the hypothesis that the nature of EET-dependent 101 contribution to HPV is a facilitating-based response via a constrictor prostanoid-mediated 102 mechanism. To this end, both in vivo and in vitro studies were conducted on sEH-knockout 103 and wild type mice to determine whether physiological presence of EETs participates in the 104 pathological process of HPV, and if so, what specific pathway(s) and/or mediator(s) are 105 involved. 106 107
Material and Methods: 108
Animals 109 12-15 week-old male C57BL/6J mice served as wild type (WT) controls, and Ephx2 -/-110 (sEH-KO) mice were used. As described previously (39), cryorecovered heterozygous (Ephx2 +/-, 111 B6.129XEphx2tm1Gonz/J) and WT mice were obtained from the Jackson Laboratory (Bar 112
Harbor, ME), and the homozygous (sEH-KO) mice were generated in the Department of 113
Comparative Medicine, New York Medical College. Another group of WT mice was fed t-114 TUCB (sEH inhibitor, 1 mg/kg/day, oral gavage) for 4 weeks. The efficiency of t-TUCB 115 treatment of mice was evidenced by a significant decrease in blood pressure, which was 116 monitored twice a week by tail-cuff measurement during the course of treatment, as described 117 previously (36). All protocols were approved by the Institutional Animal Care and Use 118
Committee of New York Medical College and conform to the guidelines of the National 119
Institutes of Health and the American Physiological Society for the use and care of laboratory 120 animals. 121 122 Surgery 123
Right ventricular catheterization was performed as described previously (21; 22). Briefly, 124 mice were anesthetized by inhalation of isoflurane and kept on a heating plate to maintain the 125 body temperature at 37 o C. After shaving the neck area, a middle incision was made to expose the 126 right and left external jugular veins. A polyethylene tube (PE-10) was placed in the left jugular 127 vein for infusion of agents such as EETs or14,15-EEZE (a putative inhibitor of EET action). 128
Another fluid-filled catheter was inserted into the right jugular vein and was advanced into the 129 right ventricle for monitoring RVSP. Yielding a stable ventricular pressure wave was indicative 130 of the catheter being successfully localized in the right ventricle. RVSP were recorded on 131
PowerLab (ADInstruments, Colorado Springs, CO) and analyzed with LabChart V8 software 132 (ADInstruments). 133
134

RVSP measurement in vivo 135
Protocol 1 aimed to assess RVSP in WT sEH-KO mice, and WT mice treated with t-136 TUCB under the control condition that was defined as breathing oxygen (100% O 2 ) enriched 137 isoflurane vapor through a nose-cone mask, and hypoxia, respectively. The isoflurane vaporizer 138 and oxygen flow were adjusted to 2% and 200ml/min, respectively (22). Hypoxia was generated 139 by replacing the oxygen tank with a tank containing 10% oxygen balanced with nitrogen, while was infused into the right ventricle of WT mice under either a control or hypoxic condition and 151 then RVSP was recorded. The selected dose has no effect on systemic blood pressure (21). 152 153
Isometric tension experiments in vitro 154
The studies were conducted on pulmonary arteries isolated from WT and sEH-KO mice 155 to identify possible mechanism(s) responsible for the EET-dependent potentiation of HPV. Mice 156 were anesthetized by isoflurane and lungs were then removed. Intra-lobar pulmonary arteries 157 were isolated and cut into rings with length of 1.46 ± 0.05 and 1.48 ± 0.06 mm in WT and KO 158 mice, respectively. The rings were mounted on a Danish myograph (DMT620M; Danish Myo 159 Technology, Aarhus, Denmark) using 40 µm stainless steel wires and perfused with Krebs-160 bicarbonate solution containing (in mM) 118 NaCl, 4.7 KCl, 1.5 CaCl 2 , 25 NaHCO 3 , 1.1 MgSO 4 , 161 1.2 KH 2 PO 4 , and 5.6 glucose and gassed with 95% air and 5% CO 2 at 37 0 C. The internal 162 circumference of each ring was originally determined by the width of the ring and the known 163 geometry of wires when the ring was stretched to a level that generated the least stretching force. 164
Based on the circumference, rings were further stretched in a stepwise manner to establish a 165 length-tension relationship. Using the length-tension curve, a baseline force that was equivalent 166 to a wall tension generated under 20 mmHg of intravascular pressure was calculated and applied 167 to the rings. The average baseline force (2.28 ± 0.15 mN and 2.24 ± 0.21 mN) and corresponding 168 diameter of rings (301.9 ± 18.9 µm and 326.4 ± 18.5 µm) were obtained from WT and sEH-KO 169 mice, respectively. This PE-induced force level (40% contraction induced by high K + ) was then, maintained in order 178 to exclude any changes in hypoxic responses attributed to an altered basal force. Hypoxia was 179 subsequently induced by gassing the Krebs solution with 95% nitrogen and 5% CO 2 for 20 180 minutes, during which, changes in hypoxic force was continuously recorded. Hypoxic force was 181 expressed as the difference between control force (PE pre-contraction) and peak force induced 182 by hypoxia for each single vessel. 183
To determine whether the enhanced endogenous EETs as a function sEH deficiency, 184 would affect HPV, hypoxia-induced force changes were assessed before and after treatment of 185 vessels of sEH-KO mice with 14,15-EEZE (10 µM). In separate experiments, hypoxic force 186 changes in vessels of WT mice were also evaluated before and after exposure of vessels to a low 187 dose of 11,12-EET (10 nM). 
Effects of exogenous EETs on RVSP 243
Changes in RVSP were recorded during the infusion of low doses of each EET 244 regioisomer into the right ventricle of WT mice to determine contribution of each EET to 245 hypoxic responses. As shown in Figure 3a , 3b, and 3d, the three EET regioisomers (5,6-; 8,9-246 and 14,15-EET) did not affect RVSP at any conditions. In contrast, 11,12-EET significantly 247 enhanced hypoxia-induced elevation of RVSP (Figure 3c ), suggesting that this EET regioisomer 248 is a primary contributor to the promotion of hypoxic elevation of RVSP. 249
250
EET-dependent potentiation of hypoxic pulmonary vasoconstriction (HPV) 251
In order to clarify the notion that in vivo increases in RVSP by hypoxia are hypoxic 252 pulmonary vasoconstriction (HPV)-based in nature, changes in pulmonary artery force in 253 response to hypoxia were determined in WT and sEH-KO mice. As shown in Figure 4 , the wall 254 tension developed as a consequence of an increase in radius (a), the force generated in response 255 to high-K + (b) and PE (c), and the relaxation to ACh (d) were comparable in vessel rings of WT 256 and sEH-KO mice. These findings suggest that both strains of mice displayed identical 257 pulmonary arterial reactivity in response to the endothelium-dependent vasodilator (ACh) and 258 vasoconstrictors (high-K + and PE) that contract vascular smooth muscle via different 259 mechanisms. In addition, they have similar wall mechanical properties in response to stretch, the 260 response that was not significantly affected by L-NAME or INDO (data not shown). Under a 261 stable vessel force maintained by PE for 20 min, switching vessels from a normoxic to hypoxic 262 environment elicited a significant increase in vessel force (as an indicative of vasoconstriction) 263 in both strains of mice (Figure 5a ), this augmentation however, was two-fold greater in sEH-KO 264 than those of WT mice (Figure 5b ), suggesting that HPV was enhanced by sEH deficiency. This 265 finding is highly consistent with the greater elevation of RVSP in response to hypoxia in sEH-266 KO mice observed in vivo (Figures 1-2) . To further confirm that the greater HPV in sEH-KO 267 mice is mediated by EETs, hypoxia-induced increases in vessel force were assessed in the 268 presence of 14,15-EEZE. Similar to observations in in vivo conditions (Figure 1) , 14,15-EEZE 269 reversed the greater HPV in vessels of sEH-KO to the level comparable to WT mice (Figure 5b) . 270
Additionally, exogenous administration of 10 nM 11,12-EET to WT vessels augmented their 271 hypoxia-induced increases in force (Figure 5c ) to the same level as sEH-KO vessels (Figure 5b) . (Figure 6a ). Intriguingly, in the presence of INDO, WT vessels 280 displayed a similar enhancement of hypoxic force to that elicited by L-NAME, suggesting that 281 vasodilator prostaglandins (PGs) compromise HPV. In contrast, increased HPV in sEH-KO 282 vessels were significantly attenuated by INDO, negating therefore, their differences from WT 283 controls (Figure 6b ). This response highlights constrictor prostanoids as responsible players in 284 the mediation of greater HPV and higher RVSP in response to hypoxia in sEH-KO mice. 285
The identity of constrictor prostanoids responsible for the greater HPV in sEH-KO mice 286 was characterized in Figure 7 . As shown in Figure 7a EETs seem to encourage the potential of hypoxic responses rather than produce it. 4) 10 nM 317 11,12-EET, which behaved similarly to other EET regioisomers in normal conditions was the 318 only regioisomer that promoted hypoxic responses (Figures 3 and 5c ), confirming its specificity 319 in the response. Finally, INDO evoked opposite actions in hypoxic force changes in vessels of 320 WT (increase) and sEH-KO mice (decrease) (Figure 5b ), a response that was also elicited by VS, 321 SQ29548 and ozagrel (Figure 7) respectively, highlighting an altered COX-1 signaling in a 322 PGH 2 /TXA 2 favorable manner, that is responsible for mediating EET-dependent potentiation of 323 hypoxic responses. 324
EET-dependent promotion of hypoxic responses 325
With respect to the action of hypoxia in CYP/EETs/sEH signal pathway, it has been 326 demonstrated that hypoxia per se suppresses activity of the CYP enzymes such as ω-hydrolase 327 (20-HETE synthase), which is extremely sensitive to changes in PO 2 (14), and EET synthase, 328 which requires O 2 for synthesis of EETs (41). Therefore it may be speculated that the 329 downstream signaling would be achieved by a decrease in CYP products in hypoxia. Our 330 previous studies demonstrated a significant increase in total tissue levels of EETs in the lung, 331 heart and vasculature of sEH-KO mice and this increment of tissue EETs resulted mainly from a 332 reduction in EET degradation, rather than increase in EET synthesis (9; 22; 36; 39). This clearly 333 explains our results, which show that exposure of mice deficient in the sEH gene (sEH-KO mice; 334 KO mice, which eliminated original differences in hypoxic force between the two strains of 370 mice (Figure 6a ), suggesting protective effects of NO on compromising HPV in both strains 371 of mice. 372 PG mediation: In physiological conditions, the balance between vasoactive prostaglandins 373 (dilators such as PGI 2 and PGE 2 versus constrictors such as PGH 2 and TXA 2 ) maintains basal 374 vascular tone. In pathological conditions, this balance can be tipped to ultimately favor 375 vasoconstriction. In this context, dysregulation of PG metabolic pathways has been reported in 376 patients with pulmonary arterial hypertension (42) and was also considered to serve as a trigger 377 in HPV (41). In addition, we have also demonstrated that an imbalance that favors actions of 378 constrictor prostanoids contributes significantly to enhanced arteriolar tone in systemic 379 hypertension (17). Studies have reached a general consensus arguing against the hypothesis that 380 decreased production of vasodilator prostaglandins (5; 6) or increased action of vasoconstrictor 381 prostanoids accounts for HPV(16), as supported by the observation that inhibition of COXs fails 382 to suppress HPV but enhances it (25-27; 41; 43; 45). Moreover, hypoxia was reported to 383 stimulate production of PGI 2 in perfused lungs and pulmonary vascular endothelium (18; 30). In 384 parallel with the aforementioned studies, we found that treatment of pulmonary arteries of WT 385 mice with INDO elicited a three-fold increase in hypoxic force compared to their control vessels 386 (Figure 5b) . Alternatively, inhibition of PGH 2 /TXA 2 failed 394 to significantly reduce HPV in WT vessels (Figure 7e-f ), revealing the negligible contribution of 395 constrictor prostanoids to the hypoxic responses in normal mice. In arachidonic acid metabolic 396 cascades, PGH 2 is an intermedium that causes vasoconstriction via binding with the PGH 2 397 receptor, and is rapidly catalyzed via TAX synthases, into TAXs with predominance in TXA 2 , 398 which constricts vessels in a TXA 2 receptor-dependent manner. As such, blocking each of the 399 up-stream or down-stream located mediators is able to prevent the constrictor responses ( Figure  400 7c-d). Thus, EETs are original initiators/players responsible for the alteration of PG-metabolism 401 to intensify PGH 2 /TXA 2 actions. In regards to how EETs tip the balance towards the constrictor 402 axis, we have no specific explanations at this moment. More likely however, EETs, via a 403 currently unknown mechanism(s), may activate and/or sensitize PGH 2 /TXA 2 receptors to 404 strengthen their actions. Such a hypothesis is supported by our previous studies indicating that 405 U46619 (TXA 2 receptor agonist) elicited a significantly greater elevation of RVSP in sEH-KO 406 than WT mice in the presence of comparable expression of the TXA 2 receptor, a response that 407 was sensitive to EEZE (22). In particular, a currently published paper clarified EETs to be 408 substrates for COX (37), providing evidence indicating that COX can serve as a target for EETs. 409
In regards to the study (23) that reveals divergent mechanisms indicating that transferring 410 TRPC6 channels to the cell membrane and activating Rho kinase are responsible for the 411 potentiation of HPV in sEH deficiency, we believed that EET-potentiating pulmonary 412 responsiveness to hypoxia is a multiple mechanism-engaged pathological process, during which, but their susceptibility to be pulmonary hypertensive when exposed to suitable environments 432 such as hypoxia might significantly increase. In this regard, our results provide a 433 mechanistically-based explanation for categorizing idiopathic pulmonary arterial hypertension as 434 a disease with female-specific prevalence (10; 31 
